We can therefore hypothesize that these variants may reduce immune response and lead to a reduced risk of iRBD and that inhibition of BST1 could become a target for future preclinical drug discovery efforts for iRBD and PD treatment or prevention. This evidence concerns the gene BST1 and Parkinson disease.